Treatment-related mortality in the HSCT arm of all included studies
| Study | N affected/ N evaluated patients | Specification |
|---|---|---|
| Treatment-related mortality | ||
| Bui-Nguyen et al21 | 1/38 | Treatment-related leukaemia death 2 years after HSCT |
| Cook et al26 | 2/36 | NR |
| Doros et al41 | 1/1 | NR |
| Engelhardt et al42 | 3/24 | Sepsis (N=2); pneumonia related to lung metastases (N=1) |
| Kasper et al43 | 1/14 | Cardiac arrest of unknown cause |
| Matsuzaki et al44 | 1/1 | Multiple organ failure |
| Navid et al45 | 1/2 | Liver as well as kidney failure |
| Philippe-Chomette et al27 | 1/14 | Died of treatment toxicity 12 months after HSCT |
| Saab et al46 | 2/4 | Acute myocardial infarction (N=1); veno-occlusive disease (N=1) |
| Slease et al47 | 2/3 | Progressive encephalopathy (N=1); sepsis (N=1) |
| Total | 15/137 | |
HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; N, number; NR, not reported.